EP2056856B1 - Méthode de traitement d'avc à l'aide d'un agent thrombolytique - Google Patents

Méthode de traitement d'avc à l'aide d'un agent thrombolytique Download PDF

Info

Publication number
EP2056856B1
EP2056856B1 EP07840638.6A EP07840638A EP2056856B1 EP 2056856 B1 EP2056856 B1 EP 2056856B1 EP 07840638 A EP07840638 A EP 07840638A EP 2056856 B1 EP2056856 B1 EP 2056856B1
Authority
EP
European Patent Office
Prior art keywords
tenecteplase
stroke
bolus
minutes
alteplase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP07840638.6A
Other languages
German (de)
English (en)
Other versions
EP2056856A2 (fr
Inventor
Peter Kuebler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38835003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2056856(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of EP2056856A2 publication Critical patent/EP2056856A2/fr
Application granted granted Critical
Publication of EP2056856B1 publication Critical patent/EP2056856B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the invention is related to a thrombolytic agent for treating stroke, more particularly, a method of administering tenecteplase in a certain dosing regimen to treat acute ischemic stroke.
  • Stroke is a general term for acute brain damage resulting from disease of the blood vessels. This presents a serious problem to society, with about 500,000 people dying from or becoming permanently disabled by stroke in the United States each year. Stroke can be classified into two main categories: hemorrhagic stroke (resulting from leakage of blood outside of the normal blood vessels) and ischemic stroke (cerebral ischemia due to lack of blood supply); this application is concerned with the latter.
  • Ischemic stroke is responsible for about one third of all deaths in industrialized countries and is the major cause of serious, long-term disability in adults over the age of 45. It stands to reason that there is a need for plarmacotherapy to treat acute ischemic stroke. Considerable insights have been gained into the mechanisms of stroke and the cascade of events that occurs following stroke; there is also an improved understanding of neuronal injury and cell death.
  • ischemic stroke The three main mechanisms of ischemic stroke are thrombosis, embolism, and systemic hypoperfusion (with resultant ischemia and hypoxia).
  • embolism the area of the brain that dies as a result of the lack of blood supply thereto.
  • infarct the area of the brain that dies as a result of the lack of blood supply thereto.
  • Obstruction of a cerebral artery resulting from a thrombus that has built up on the wall of a brain artery is generally called “cerebral thrombosis.”
  • cerebral embolism the occlusive material blocking the cerebral artery arises downstream in the circulation (e.g., an embolus is carried to the cerebral artery from the heart).
  • thromboembolism is used to cover both these types of stroke.
  • Systemic hypoperfusion may arise as a consequence of elevated blood lactate levels, reduced hematocrit, low blood pressure, or inability of the heart to pump blood adequately.
  • TIA transient ischemic attack
  • Acute ischemic stroke is a heterogeneous disease process; prediction of course, recovery, disability, or death is difficult. It is typically due to an acute thromboembolic arterial occlusive lesion. The location of the arterial occlusive lesion in acute ischemic stroke is relatively heterogeneous.
  • Thrombolytic agents such as recombinant tissue plasminogen activator (rtPA) have been used in the treatment of thromboembolic stroke, and function by lysing the thrombus causing the ischemia.
  • rtPA recombinant tissue plasminogen activator
  • intravenous rtPA (alteplase, ACTIVASE®) is the only drug approved for the treatment of acute ischemic stroke.
  • Intravenous rtPA (0.9 mg/kg, maximum 90 mg), with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes, is recommended treatment within 3 hours of onset of ischemic stroke.
  • This drug is believed to be most useful if administered as soon as possible after acute stroke ( Gross et al., Neurosurgery, 36:1172-1177 (1995 ); Ingall et al., Stroke, 35: 2418-2424 (2004 ); The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators, Lancet, 363: 768-774 (2004 )), to restore, partially at least, cerebral blood flow in the ischemic region and to sustain neuronal viability.
  • Thrombolysis the lysis of a cerebral arterial clot with tPA within hours of symptom onset in ischemic stroke, has been approved for treatment of acute ischemic stroke since 1996.
  • Two other agents pro-urokinase (intra-arterial administration directly into M1 or M2 arterial thrombus) and intravenous ancrod, a fibrinogen-lowering agent derived from the venom of the Malayan pit viper, have shown therapeutic benefit, and may be available for acute ischemic stroke therapy in the future.
  • pro-urokinase intra-arterial administration directly into M1 or M2 arterial thrombus
  • intravenous ancrod a fibrinogen-lowering agent derived from the venom of the Malayan pit viper
  • 2002/0081294 and US 2004/0057951 disclose co-administration of a thrombolytic compound and an anti-CD 18 antibody for increasing blood flow in an infarct-related artery in a mammal such as a human (e.g., acute myocardial infarction (AMI) in a mammal with a blocked coronary artery or focal ischemic stroke caused by obstruction of a cerebral artery).
  • a mammal such as a human
  • AMI acute myocardial infarction
  • U.S. Pat. No. 6,541,452 discloses a brain-associated inhibitor of tPA and its use in treating stroke.
  • US Pat. Pub. 2004/0176347 discloses a pharmaceutical composition for treating cerebral ischemic diseases comprising an astrocyte-function-improving agent and a thrombolytic agent, preferably tPA, as active ingredients.
  • Tenecteplase (TNK, TNKASETM, Genentech, Inc., South San Francisco, CA) is a genetically engineered variant of human tPA cloned and expressed in Chinese hamster ovary cells. Keyt et al., Proc. Natl. Acad. Sci USA, 91: 3670-3674 (1994 ). See also Verstraete, Am. J. Med., 109: 52-58 (2000 ) for an overview of third-generation thrombolytic drugs in general. Approved in the U.S. for a single-bolus administration in patients with AMI, tenecteplase was engineered to have increased fibrin specificity and an increased half-life compared to alteplase.
  • Tenecteplase and alteplase were equivalent for 30-day mortality when single-bolus tenecteplase was compared with front-loaded alteplase in acute myocardial infarction in the ASSENT-2 double-blind randomized trial.
  • the ease of administration of tenecteplase may facilitate more rapid treatment in and out of the hospital. Van de Werf et al., Lancet, 354: 716-722 (1999 ).
  • the results of the ASSENT-2 study indicated that total stroke rate and 30-day mortality were lower in female patients over 75 years of age treated with tenecteplase than in those treated with alteplase, albeit that the difference was statistically not significant.
  • thrombolytic agents that is given according to a weight-adjusted dose regimen, e.g., tenecteplase. Vermeer, Thrombosis Research, 103: Supplement 1, S101-S104 (September 30 2001 ).
  • Other thrombolytic drugs that may be useful in treating AMI include streptokinase, urokinase, anistreplase,reteplase, saruplase, reteplase, lanoteplase, staphylokinase, fibrolase, prourokinase, and vampire bat plasminogen activator.
  • Tenecteplase was found to be effective in treating AMI in combination with the low-molecular-weight heparin enoxaparin (ENOX) or unfractionated heparin in the prehospital setting in a trial called ASSENT-3 PLUS.
  • ENOX low-molecular-weight heparin enoxaparin
  • ASSENT-3 PLUS unfractionated heparin in the prehospital setting in a trial called ASSENT-3 PLUS.
  • the combination of tenecteplase with ENOX reduces early ischemic events, but lower doses of ENOX need to be tested in elderly patients.
  • the animal data also show that, overall, the beneficial effects of the neuroprotective agents are weaker, and are totally lost sooner, than those of thrombolytics.
  • the human data show that the failed trials of the neuroprotective agents had entry windows that went far beyond the windows of (any) success seen in tests of these agents in animals.
  • human thrombolysis trials uniformly restricted time of entry to windows in which these agents have shown beneficial effect in animals.
  • neuroprotective agents failed to produce benefit because their effects at best are too weak, and they were used at times predictable from the animal models as too late.
  • Thrombolytic therapy such as tenecteplase and urokinase, which has a stronger effect than neuroprotective agents in animal models, was used clinically during the early window of optimal effectiveness, and produced beneficial results.
  • third-generation thrombolytics Two of the several third-generation thrombolytic agents have been investigated for the treatment of acute ischemic stroke and include tenecteplase and reteplase. By virtue of structural modifications, third-generation thrombolytics have longer half-lives and greater penetration into the thrombus matrix.
  • the first prospective human clinical trial evaluated the safety and efficacy of intra-arterial reteplase in 16 patients with ischemic stroke who were poor candidates for intravenous alteplase therapy.
  • monteplase a modified rtPA
  • Other such third-generation drugs include lanoteplase, plasmin, or a truncated form of plasmin (microplasmin), a direct-acting thrombolytic with non-thrombolytic-related neuroprotective, therapeutic activities, recombinant desmodus rotundus salivary plasminogen activator (rDSPA) alpha-1, and a mutant fibrin-activated human plasminogen (BB10153; British Biotech Inc.).
  • CLEAR stroke study A multi-center, randomized, double-blinded sequential dose-escalation clinical trial called the CLEAR stroke study is now being conducted to evaluate the safety of eptifibatide, an intravenous cyclical heptapeptide that selectively blocks the platelet glycoprotein IIb/ IIIa receptor, in combination with low-dose rtPA in acute ischemic stroke treated within three hours.
  • tenecteplase may be neuroprotective following a stroke because of its increased fibrin specificity over alteplase, its resistance to PAI-1, and its increased biological half-life (18 vs. 10 minutes for alteplase), features that could lead to fewer cerebral hemorrhages than alteplase in stroke patients.
  • tenecteplase A pilot study of tenecteplase was made in 88 acute ischemic stroke patients enrolled over 2000 to 2003 using four dose tiers of tenecteplase: 0.1, 0.2, 0.4, and 0.5 mg/kg. There were no symptomatic intracranial hemorrhages (ICHs) in the first three tiers. Two of 13 patients had symptomatic ICH at 0.5 mg/kg, and there were increasing ICHs with increasing doses (8% - 38%), with outcomes similar to the alteplase group in the earlier acute ischemic stroke trial.
  • ICHs intracranial hemorrhages
  • Tenecteplase is currently being tested in a randomized controlled Phase IIb clinical study in acute ischemic stroke patients using 0.1 mg/kg tenecteplase, 0.4 mg/kg tenecteplase, and 0.9 mg/kg rtPA.
  • tenecteplase In an early animal study, the activity of tenecteplase was compared with that of alteplase in rabbit models of embolic stroke and peripheral bleeding. Infusion of alteplase or bolus administration of the tenecteplase resulted in dose-dependent clot lysis. The tenecteplase was found to be an order of magnitude more potent than alteplase on a milligram-per-kilogram basis. Unlike alteplase, tenecteplase caused less systemic activation of plasminogen and fewer hemorrhagic transformations in this model. The tenecteplase did not extend template bleeding times.
  • tenecteplase in a dose of using 0.6 mg/kg or 1.5 mg/kg was compared with wild-type tPA in a rabbit embolic stroke model. Both wild-type tPA and tenecteplase caused thrombolysis in most subjects, and did not differ from each other. Neither tenecteplase nor tPA affected the size of the hemorrhages. Tenecteplase shows comparable rates of recanalization compared with wild-type tPA in a model of embolic stroke. While tPA increases hemorrhage rate, the hemorrhage associated with tenecteplase treatment is not statistically different compared with controls or the tPA group.
  • 188(2) 279-85(2004 ) discloses the window for acute stroke treatment of thrombolytics such as tenecteplase plus central-nervous-system (CNS)-protective therapies such as free-radical scavengers, NXY 059, and nitrogen oxides.
  • CNS central-nervous-system
  • Lapchak et al., Experimental Neurology, 185: 154-159 (2004 ) discloses a comparison of tenecteplase with alteplase on clinical rating scores following small-clot embolic strokes in rabbits.
  • the rabbit small clot embolic stroke model (RSCEM) was used for a dose-response profile analysis of tenecteplase (0.1 mg/kg-3.3 mg/kg) and alteplase (0.9 mg/kg-3.3 mg/kg) given intravenously 1 hour following embolization.
  • tenecteplase (0.9 mg/kg) or alteplase (3.3 mg/kg) was administered 3 (or 6) hours following embolization to determine the therapeutic window for the thrombolytics.
  • behavioral analysis was conducted 24 hours following embolization, allowing for the determination of the effective stroke dose (P50) or clot amount (mg) that produces neurological deficits in 50% of the rabbits.
  • tenecteplase has a wide therapeutic range, a therapeutic window of at least 3 hours, and a durable effect. Moreover, the safety profile for tenecteplase is similar to that of alteplase. Tenecteplase does not increase the rate of intracerebral hemorrhage (ICH) above that produced by alteplase. However, the therapeutic range and window for alteplase is more limited than that for tenecteplase. These preclinical studies suggest that tenecteplase has a better pharmacological profile than alteplase and supports further investigation of tenecteplase in randomized double-blinded clinical trials in stroke patients.
  • the invention provides tenecteplase for use in treating acute ischemic stroke in a human comprising administering tenecteplase to the human in a total dose of about 0.05 to 0.5 mg/kg, given as an initial bolus dose of about 0.015 to 0.15 mg/kg, followed by infusion of an amount equaling the total dose minus the initial dose over a period of about 50-90 minutes.
  • tenecteplase is administered to the human in the form of a pharmaceutically acceptable formulation, such as those elaborated in more detail herein.
  • the total dose is about 0.2 to 0.3 mg/kg, more preferably about 0.25 mg/kg.
  • the total dose is given as an initial bolus followed by the infusion.
  • the initial dose is about 0.08 to 0.12 mg/kg, more preferably about 0.1 mg/kg bolus, and/or the period of infusion is about 55-70 minutes, more preferably about 60 minutes.
  • the total dose is about 0.25 mg/kg, given as an initial about 0.1 mg/kg bolus, followed by infusion of about 0.15 mg/kg over about 60 minutes.
  • tenecteplase is administered to the human in a total dose of about 0.25 mg/kg in about 60 minutes, given as an initial bolus of about 0.1 mg/kg over one minute, followed by infusion of about 0.25 mg/kg for the rest of about 60 minutes.
  • the tenecteplase is administered to the human at a time between about 15 minutes to about 20 hours from the onset of acute ischemic stroke, more preferably between about 45 minutes to about 6 hours, and still more preferably up to no more than about 3 hours from the onset of acute ischemic stroke.
  • the bolus is intravenous and/or the infusion is continuous.
  • the treatment further comprises administering to the human an effective amount of a second medicament, wherein the first medicament is tenecteplase.
  • This second medicament is preferably a neuroprotective agent, a thrombolytic agent, a glycoprotein IIb IIIa antagonist, or an anti-CD18 antibody.
  • This second medicament may be co-administered to the human either before, after, or simultaneously with, the tenecteplase.
  • Such second medicament may be administered to the mammal more than about 3 hours after the onset of ischemic stroke ( e.g., at least once within about 3-8 hours and preferably within about 3-6 hours from the onset of stroke).
  • kits comprising: a container comprising tenecteplase; and instructions for using the tenecteplase to treat acute ischemic stroke in a human by administering the tenecteplase to the human in a total dose of about 0.05 to 0.5 mg/kg, given as (a) an initial bolus dose of about 0.015 to 0.15 mg/kg, followed by infusion of an amount equaling the total dose minus the initial dose over a period of about 50-90 minutes, or (b) a bolus.
  • kits may further comprise a container comprising a second medicament, wherein the instructions include instructions for using the second medicament in combination with the tenecteplase to treat ischemic stroke in a human by administering to the human an effective amount of the second medicament.
  • the preferred second medicament is a neuroprotective agent, a thrombolytic agent, a glycoprotein IIb IIIa antagonist, or an anti-CD18 antibody.
  • Stroke is defined herein as a neurologic deficit caused by a cerebrovascular accident (CVA), which disrupts the blood supply to the brain for at least 24 hours. Stroke may take different forms, including hemorrhagic stroke and ischemic stroke, where each may be further subdivided. Thus, for example, hemorrhagic stroke may be characterized by a sudden development of neurological deficit with ICH or subarachnoid hemorrhage (SAH), while subtypes of ischemic stroke include lacunar, thromboembolic, and cardioembolic strokes.
  • SAH subarachnoid hemorrhage
  • ischemic stroke include lacunar, thromboembolic, and cardioembolic strokes.
  • stroke is used herein in the broadest sense, and includes all forms of stroke, whether specifically listed herein or not.
  • Transient ischemic attack or “TIA” is defined herein as a temporary disruption in the blood supply to the brain, which is resolved completely within 24 hours, and usually lasts minutes to an hour.
  • Acute ischemic stroke is defined herein as an acute development of focal or global disturbance of cerebral function due to thromboembolism lasting more than 24 hours or leading to death.
  • An acute focal ischemic stroke is damage to the brain caused by interruption of the blood supply to a region thereof.
  • the acute ischemic stroke of interest herein is generally caused by obstruction of any one or more of the arteries, including the main cerebral arteries (e.g., middle cerebral artery, anterior cerebral artery, posterior cerebral artery, internal carotid artery, vertebral artery or basilar artery), and secondary arteries or arterioles.
  • the "arterial obstruction” is generally a single embolus or thrombus or a plurality of clot particles that occlude primary and secondary arteries or arterioles.
  • IVH intraventricular hemorrhage
  • grade 1 bleeding occurs in a small area of the ventricles
  • grade 2 bleeding also occurs inside of the ventricles
  • grade 3 ventricles are enlarged by the blood
  • grade 4 bleeding extends into the brain tissue around the ventricles.
  • increasing cerebral blood flow or reducing infarct size is meant the act of improving clinical outcome by inducing a statistically or physiologically significant increase in cerebral blood flow and/or a statistically or physiologically significant reduction in infarct size in a treated mammal relative to an untreated mammal as determined using techniques that are well known in the art, such as vascular imaging, for example.
  • cerebral blood flow as determined 2-4 hours after administration of the antagonist is increased by at least 30% and preferably at least 50% relative to an untreated mammal.
  • infarct size measured 48 hours after administration of the antagonist will be 20% less and preferably 50% less than that of an untreated mammal.
  • infarct is an area of necrosis in a tissue or organ, for example, heart or brain, resulting from obstruction of the local circulation by a thrombus or embolus. Infarct size can be measured by known methods.
  • an "infarct-related artery” is an artery that, when at least partially blocked by a thrombus or embolus, gives rise to an infarct in a tissue or organ, for example, heart or brain.
  • Treatment refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented. Preferred herein is the treatment of those individuals who have been diagnosed as having suffered stroke, in particular, acute ischemic stroke.
  • tenecteplase also known as TNK-tPA or TNKASETM brand of tissue-plasminogen activator variant, refers to a tPA variant designated T103N, N117Q, K296A, H297A,R298A,R299A tPA available from Genentech, Inc.
  • a "package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications, other therapeutic products to be combined with the packaged product, and/or warnings concerning the use of such therapeutic products, etc.
  • a “medicament” is an active drug to treat stroke or its symptoms or side effects.
  • a "second medicament” is one that can be added to help the first medicament, tenecteplase, to treat the stroke.
  • second medicaments include, without limitation, aspirin, intercellular adhesion molecule (ICAM)-1 and LFA-1 antagonists including antibodies such as enlimomab (an anti-ICAM-1 monoclonal antibody), and anti-CD18 and anti-CD11a antibodies, human anti-leukocytic antibodies such as Hu23F2G, glycoprotein IIb IIIa antagonists such as eptifibatide (INTEGRELINTM) (an intravenous cyclical heptapeptide that selectively blocks the platelet glycoprotein IIb/ IIIa receptor), direct thrombin inhibitors, external or local ultrasound, mechanical clot retrieval or inaceration, fibrinolytic agents, neuronal wound healing agents such as basic fibroblast growth factor (e.g., FIBLASTTM), neuroprotective agents such as citicoline, magnesium, nalmefene, dizocilpine
  • a "thrombolytic agent” is a molecule that breaks up and/or dissolves a thrombus.
  • exemplary thrombolytic agents include streptokinase, acylated plasminogen-streptokinase activator complex (APSAC), urokinase, single-chain urokinase-plasminogen activator (scu-PA), thrombin-like enzymes from snake venoms such as ancrod ( Bell, W. "Defibrinogenating enzymes" In Colman et al., (eds): Hemostasis and Thrombosis Lippincott, Philadelphia (1987) p. 886 ), tPA, and biologically active variants of each of the above.
  • Suitable thrombolytic agents that may be used in this invention are disclosed, for example, in U.S. Patent Nos. 5,770,425 ; 5,770,426 ; 5,612,029 ; 5,520,911 ; 5,736,134 ; 5,728,567 ; 5,714,145 ; 5,840,564 ; 5,616,486 ; 5,411,871 ; 5,520,913 ; 5,262,170 ; and 5,108,901 .
  • Co-administration means the administration of the second medicament during the effective therapeutic window of the tenecteplase administered alone.
  • the second medicament may be administered before, concurrent with, or after the tenecteplase.
  • the administration of the second medicament such as anti-CD18 antibody, is preferably started from about 1 hour before up to immediately (1-15 minutes) before, more preferably concurrently with, the start of administration of the tenecteplase.
  • Co-administration also encompasses administration of the second medicament after the start of administration of the tenecteplase, for example about 15-30 minutes after and up to about 3 hour after.
  • Co-administration includes administration in the form of a single formulation, where the two medicaments may be, but do not have to be, physically separated from each other.
  • the "effective therapeutic window" of tenecteplase administered alone means the time period or time window following an infarct caused by blockage of an artery during which the tenecteplase, when administered alone, is effective in reestablishing patency of blood flow in the artery relative to a control not receiving the tenecteplase.
  • the effective therapeutic window is species dependent for tenecteplase, but can be readily determined by standard tests evaluating the efficacy of the tenecteplase versus controls.
  • anti-CD 18 antibody when used herein refers to an antibody that binds to CD18 (preferably human CD18) and inhibits or substantially reduces a biological activity of CD18. Normally, the antibody will block (partially or completely) the ability of a cell (e.g., a neutrophil) expressing the CD18 subunit at its cell surface to bind to endothelium.
  • a cell e.g., a neutrophil
  • anti-CD18 antibodies examples include MHM23 (Hildreth et al. (1983)); M18/2 (IgG 2a ; Sanches-Madrid et al., Eur. J. Immunol. 13(3):202-208 (1983 )); H52 (American Type Culture Collection (ATCC) Deposit HB 10160); Mas191c and IOT18 ( Vermot Desroches et al., Scand. J. Immunol. 33(3):277-286 (1991 )); and NA-8 ( WO 94/12214 ).
  • the preferred antibody is one that binds to the CD18 epitope to which either MHM23 or H52 binds.
  • the antibody has a high affinity for the CD18 polypeptide.
  • the antibody has an affinity for the CD18 antigen of about 4 nM or less.
  • the affinity is about 3 nM or less, and most preferably about 1 nM or less.
  • the antibody may bind to a region in the extracellular domain of CD18 that associates with CD11b and the antibody may also dissociate alpha and beta chains ( e.g ., the antibody may dissociate the CD11b and CD18 complex, as is the case for the MHM23 antibody).
  • the present invention provides an improved protocol for the treatment of stroke, in particular acute ischemic stroke, with tenecteplase.
  • the treatment protocols and dosing regimens of the present invention result in pharmacokinetic profiles that offer maximum efficacy and safety, and thus represent a significant advance in the thrombolytic therapy of stroke.
  • the invention provides a treatment for acute ischemic stroke in a human comprising administering to the human tenecteplase in a total dose of about 0.05 to 0.15 mg/kg (preferably about 0.2 to 0.3 mg/kg, and more preferably about 0.25 mg/kg), given as an initial dose of about 0.015 to 0.15 mg/kg bolus (preferably about 0.08 to 0.12 mg/kg bolus, more preferably about 0.1 mg/kg bolus), followed by infusion of the remaining amount to total about 0.05 to 0.5 mg/kg (preferably about 0.2 to 0.3 mg/kg, more preferably about 0.25 mg/kg) over a period of about 50-90 minutes, more preferably about 55-70 minutes, and most preferably about 60 minutes.
  • the initial bolus dose is preferably about 0.1 mg/kg and the subsequent infusion is about 0.15 mg/kg. Based on current experiments, this is the most preferred regimen, wherein the subsequent infusion is given over about 60 minutes. It is noted, however, that the most preferred dosing schedule might vary within the specified dosing ranges, depending on various factors, including the specific type and extent of stroke, the condition of the patient, the time elapsed from the onset of stroke, and the like.
  • the infusion of tenecteplase may follow immediately after the bolus dose is complete, or can be separated from completion of the bolus dosage by up to about 30 minutes, but it is preferred to initiate the infusion immediately after the bolus dose is completed.
  • the bolus injection is intravenous, but it may be injected by other means such as intra-arterially.
  • the infusion is continuous by intravenous, intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, or intrathecal routes, but the preferred infusion is intravenous.
  • acute ischemic stroke is treated in a human by administering tenecteplase in a total dose of about 0.05 to 0.15 mg/kg, preferably about 0.2 to 0.3 mg/kg, more preferably about 0.25 mg/kg, given exclusively as a bolus dose.
  • the bolus is intravenous.
  • Stroke is a serious condition and the third leading cause of death in the United States. Since survival and the extent of recovery are a function of the time of diagnosis and intervention, in the methods of the present invention it is contemplated that the tenecteplase will be administered to a patient as soon as possible once the condition of acute ischemic stroke has been diagnosed or is suggested by acute deficit on neurologic examination.
  • Initial clinical presentations of acute ischemic stroke typically include one or more of (1) alterations in consciousness, such as stupor or coma, confusion or agitation, memory loss, seizures, and/or delirium; (2) headache that is intense or unusually severe, is associated with decreased level of consciousness/neurological deficit, and/or includes unusual/severe neck or facial pain; (3) aphasia (incoherent speech or difficulty understanding speech); (4) facial weakness or asymmetry; (5) uncoordination, weakness, paralysis, or sensory loss of one or more limbs; (6) ataxia (poor balance, clumsiness, or difficulty walking); (7) visual loss; and (8) intense vertigo, double vision, unilateral hearing loss, nausea, vomiting and/or photophobia.
  • the presence of one or more of these manifestations might be an initial indication of acute ischemic stroke, which can be verified by follow-up differential diagnosis and neurological examination.
  • Neurologic examination and, optionally, neuroimaging techniques such as computed tomography (CT) (including non-contrast CT and perfusion CT) and magnetic resonance imaging (MRI) (including diffusion weighted imaging (DWI) and perfusion imaging (PI)); vascular imaging (e.g., duplex scanning and transcranial Doppler ultrasound and laser Doppler); and angiography (e.g., computerized digital subtraction angiography (DSA) and MR angiography) as well as other invasive or non-invasive techniques, are available for the diagnosis of acute ischemic stroke.
  • CT computed tomography
  • MRI magnetic resonance imaging
  • DWI diffusion weighted imaging
  • PI perfusion imaging
  • vascular imaging e.g., duplex scanning and transcranial Doppler ultrasound and laser Doppler
  • angiography e.g., computerized digital subtraction angiography (DSA) and MR angiography
  • DSA computerized digital subtraction angiography
  • NIHSS National Institute of Health Stroke Scale
  • the tenecteplase will be administered in the dosage and dosage regimen herein at least once at any time from immediately following to about 24 hours after the onset of stroke.
  • the tenecteplase is first administered to the patient between about 15 minutes (or about 30 or 45 minutes) to about 20 hours (more preferably about 10 hours, or about 6 hours, or 3 hours, or about 90 minutes, or about 60 minutes) from the onset of stroke.
  • a patient presenting within 3 hours of the onset of signs and symptoms consistent with an acute ischemic stroke is subjected to thrombolytic therapy with tenecteplase in accordance with the present invention.
  • the second medicament may be one or more medicaments, and may include, for example, those set forth above.
  • Preferred such medicaments include neuroprotective agents, anticonvulsive agents, a spin-trap agent, intercellular adhesion molecule (ICAM)-1 and LFA-1 antagonists such as anti-CD11a and anti-CD18 antibodies, glycoprotein IIb IIIa antagonists, neuronal wound healing agent, antibodies inhibiting platelet aggregation and adhesion, and human anti-leukocytic antibodies, or another thrombolytic agent than tenecteplase. More preferred are neuroprotective agents, other thrombolytic agents, glycoprotein IIb IIIa antagonists, and anti-CD18 antibodies.
  • second medicaments are generally used in the same dosages and with administration routes as used hereinbefore or about from 1 to 99% of the heretofore-employed dosages. If such second medicaments are used at all, preferably, they are used in lower amounts than if the tenecteplase were not present, especially in subsequent dosings beyond the initial dosing with tenecteplase, so as to eliminate or reduce side effects caused thereby.
  • a second medicament is administered in an effective amount with a tenecteplase bolus dosing, it may be administered with any such dosing, for example, only with one such dosing, or with more than one such dosing.
  • the second medicament is administered with the initial bolus dosing.
  • the second medicament is administered with the first and second dosings.
  • the second medicament is administered with all tenecteplase dosings.
  • the combined administration includes co-administration (concurrent administration), using separate formulations or a single pharmaceutical formulation, and consecutive administration in either order, wherein preferably there is a time period while both (or all) active agents simultaneously exert their biological activities. It is preferred that after the initial exposure, the amount of such agent is reduced or eliminated so as to reduce the exposure of the subject to an agent with side effects such as prednisone and cyclophosphamide.
  • a device such as an INTERCOOLTM device and/or using external ice at 33°C or a similar temperature may be employed along with the tenecteplase for treating the stroke.
  • Therapeutic formulations of the tenecteplase are prepared for storage by mixing the tenecteplase having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers ( Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980 )), in the form of lyophilized formulations or aqueous solutions.
  • Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, trehalose or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEENTM, PLURONICSTM or PEG.
  • buffers such as phosphate, citrate and other organic acids
  • antioxidants including ascorbic acid
  • low molecular weight (less than about 10 residues) polypeptides proteins
  • the active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • the formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution.
  • sustained-release preparations may be employed. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the tenecteplase, which matrices are in the form of shaped articles, e.g ., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides ( U.S. Pat. No.
  • copolymers of L-glutamic acid and ⁇ ethyl-L-glutamate copolymers of L-glutamic acid and ⁇ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOTTM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
  • encapsulated antibodies When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
  • Sustained-release tenecteplase compositions also include liposomally entrapped tenecteplase.
  • Liposomes containing the tenecteplase are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82:3688 (1985 ); Hwang et al., Proc. Natl Acad. Sci. USA, 77:4030 (1980 ); and U.S. Pat. Nos. 4,485,045 and 4,544,545 .
  • the liposomes are the small (about 200-800 Angstroms) unilamelar type in which the lipid content is greater than about 30 mol.% cholesterol, the selected proportion being adjusted for the optimal tenecteplase therapy.
  • Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556 .
  • tenecteplase The exact total dosage of tenecteplase to be employed, and how much is by bolus and how much by infusion, or whether only bolus should be employed, will depend, for example, on the exact nature of the stroke to be treated, the severity and course of the stroke, whether the tenecteplase is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the tenecteplase, and the discretion of the attending physician. The progress of this therapy is easily monitored by conventional techniques and assays elaborated herein.
  • the article of manufacture comprises a container with a label.
  • Suitable containers include, for example, bottles, vials, and test tubes.
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container holds a composition that is effective for treating stroke as defined herein and may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • the active agent in the composition is tenecteplase.
  • the label on the container indicates that the composition is used for treating stroke as described above, and may also indicate directions for in vivo use, such as those described above.
  • the kit comprises a container comprising tenecteplase and instructions for using the tenecteplase to treat acute ischemic stroke in a human by administering the tenecteplase to the human in a total dose of about 0.05 to 0.5 mg/kg, given as (a) an initial bolus dose of about 0.015 to 0.15 mg/kg, followed by infusion of an amount equaling the total dose minus the initial dose over a period of about 50-90 minutes, or (b) a bolus.
  • the total dose is about 0.2 to 0.3 mg/kg, more preferably about 0.25 mg/kg
  • the initial dose under option (a) above is about 0.08 to 0.12 mg/kg, more preferably about 0.1 mg/kg.
  • the total dose is given as an initial bolus followed by the infusion.
  • the total dose is about 0.25 mg/kg, given as an initial about 0.1 mg/kg bolus, followed by infusion of about 0.15 mg/kg over about 60 minutes.
  • the total dose is given as a bolus.
  • kits may optionally also comprise a container holding a second medicament, wherein the instructions include directions for using the second medicament in combination with the tenecteplase to treat ischemic stroke in a human by administering to the human an effective amount of the second medicament.
  • the instructions include directions for using the second medicament in combination with the tenecteplase to treat ischemic stroke in a human by administering to the human an effective amount of the second medicament.
  • Exemplary second medicaments and preferred second medicaments are noted above.
  • kits may also comprise another container comprising a pharmaceutically acceptable buffer, such as phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
  • a pharmaceutically acceptable buffer such as phosphate-buffered saline, Ringer's solution, and dextrose solution.
  • a pharmaceutically acceptable buffer such as phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
  • a dosing strategy that improves the safety and efficacy of the treatment of AIS with tenecteplase was developed by performing PK modeling.
  • PK analysis of a rabbit in-vivo PK and pharmacodynamic (PD) study suggested that alteplase and TNKase were approximately equipotent when comparing the area under the curve (AUC) and time to 50% clot lysis ( Thomas et al. Stoke, 25/10 2072-2078 (1994 )).
  • AUC area under the curve
  • PD pharmacodynamic
  • PK modeling was performed using historical alteplase acute myocardial infarct (AMI) PK data as well as TNKase data in AMI and stroke to an provide appropriate dose of TNKase for AIS.
  • AMI acute myocardial infarct
  • a bolus of 0.25 mg/kg bolus was the 2nd choice for a TNKase dose in AIS dosing strategy.
  • the TNKase dosing regimens were derived using a modeling and simulation approach intended to recapitulate the exposure and concentration time profile of alteplase during the treatment period associated with the USPI dosing of 0.9 mg/kg (10% bolus over 1 minute and 90% over the remainder of an hour).
  • PK model an alteplase structural and error model
  • PPK model TNKase population PK model
  • TNKase PPK model was derived using individual patient serum concentration data from the AMI trial TIMI10B (Modi et al., supra ) and a pilot dose-escalating AIS trial. The combined data were best described using a two-compartment model. The final model results are summarized in Table II. Table II TNKase (Tenecteplase) Final Model Estimates Parameter Model Result Parameter estimate (SEE) Method FOCE with INTER No.
  • ⁇ L is the population estimate of CL
  • CL j is the individual CL
  • WT j is the individual weight with 81.8 as the median weight
  • AGE j is the individual age with 58 as the median age.
  • the basis for the TNKase dosing regimens was the concentration-time profile and exposure of the USPI dosing regimen for alteplase during the 60-minute treatment period ( Figure 1 ).
  • the strategy was to use this as an approximate target for TNKase dosing.
  • Figure 1 suggested that the 10% alteplase bolus results in near steady-state drug concentrations, followed by a fairly constant concentration of alteplase for the remaining 60 minutes.
  • Model-estimated median concentration values obtained at two-minute intervals from 2-60 minutes were then used to calculate mean effective concentration (computer program JMP version 5.1. 2003) (SAS Institute Inc.) and the AUC.
  • the first TNKase regimen for stroke included a bolus followed by a constant infusion.
  • the required bolus dose to get to the mean effective concentration was derived by the following formula:
  • Bolus dose V ⁇ ⁇ d x C effective
  • Thereteplase exposure was defined as the AUC 0-60 minutes.
  • the mean effective concentration for alteplase was approximately 1800 ng/mL, resulting in an AUC of 108,000 ng*min/mL.
  • the total TNKase dose required to maintain a concentration and exposure approximating the effective concentration was 0.16 mg/kg administered over 1 hour.
  • TNKase a dose of TNKase of 0.25 mg/kg administered as 0.1 mg/kg bolus over 1 minute and 0.15 mg/kg over the remainder of 1 hour was determined as an appropriate dosing regimen for TNKase in AIS.
  • the intent was to administer higher early doses to improve clot lysis (consistent with what has been observed with alteplase in AMI) without altering fibrinogen or increasing the risk of bleeding.
  • This bolus regimen also would reduce the low-level exposure at later time points observed with the bolus-infusion regimen.
  • Figure 3 shows the median model-predicted alteplase concentrations with the model-predicted TNKase median, 5 th , and 95 th percentile concentrations from the 0.25 mg/kg bolus regimen.
  • Table IV summarizes the AUC values and compares concentrations at key timepoints. Overall, the exposure and concentration time curves observed from simulating a 0.25 mg/kg bolus suggested that this regimen for bolus-only treatment was appropriate.
  • bolus-infusion and bolus-only dosing regimens of TNKase for use in treating acute ischemic stroke were determined using pharmacokinetic modeling and simulation. These dosing regimens were designed to provide improved safety and efficacy from tenecteplase as compared to alteplase when administered to AIS patients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Claims (14)

  1. Ténectéplase pour une utilisation dans le traitement d'un accident vasculaire cérébral ischémique aigu chez un être humain, dans laquelle le ténectéplase est administré à une dose totale d'environ 0,05 à 0,5 mg/kg, donnée sous la forme d'une dose bolus initiale d'environ 0,05 à 0,15 mg/kg, suivie d'une perfusion d'une quantité égale à la dose totale moins la dose initiale sur une période d'environ 50 à 90 minutes.
  2. Ténectéplase pour une utilisation selon la revendication 1, dans laquelle la dose totale est d'environ 0,2 à environ 0,3 mg/kg.
  3. Ténectéplase pour une utilisation selon la revendication 1 ou 2, dans laquelle la dose totale est d'environ 0,25 mg/kg.
  4. Ténectéplase pour une utilisation selon l'une quelconque des revendications 1 à 3, dans laquelle la dose initiale est un bolus d'environ 0,08 à 0,12 mg/kg.
  5. Ténectéplase pour une utilisation selon l'une quelconque des revendications 1 à 4, dans laquelle la dose initiale est un bolus d'environ 0,1 mg/kg.
  6. Ténectéplase pour une utilisation selon l'une quelconque des revendications 1 à 5, dans laquelle la période de perfusion est d'environ 55 à 70 minutes.
  7. Ténectéplase pour une utilisation selon l'une quelconque des revendications 1 à 6, dans laquelle la période de perfusion est d'environ 60 minutes.
  8. Ténectéplase pour une utilisation selon l'une quelconque des revendications 1 à 7, dans laquelle la dose totale est d'environ 0,25 mg/kg, donnée sous forme d'un bolus initial d'environ 0,1 mg/kg, suivi d'une perfusion d'environ 0,15 mg/kg sur environ 60 minutes.
  9. Ténectéplase pour une utilisation selon l'une quelconque des revendications 1 à 8, dans laquelle le ténectéplase est administré à l'être humain à un moment compris entre environ 15 minutes et 20 heures à partir de la manifestation de l'accident vasculaire cérébral ischémique aigu.
  10. Ténectéplase pour une utilisation selon l'une quelconque des revendications 1 à 9, dans laquelle le ténectéplase est administré à l'être humain à un moment compris entre environ 30 minutes et 6 heures à partir de la manifestation de l'accident vasculaire cérébral ischémique aigu.
  11. Ténectéplase pour une utilisation selon l'une quelconque des revendications 1 à 10, dans laquelle le ténectéplase est administré à l'être humain à un moment compris entre environ 30 minutes et 3 heures à partir de la manifestation de l'accident vasculaire cérébral ischémique aigu.
  12. Ténectéplase pour une utilisation selon l'une quelconque des revendications 1 à 11, dans laquelle le bolus est intraveineux.
  13. Ténectéplase pour une utilisation selon l'une quelconque des revendications 1 à 12, dans laquelle le ténectéplase est administré en combinaison avec une quantité efficace d'un second médicament.
  14. Ténectéplase pour une utilisation selon la revendication 13, dans laquelle le second médicament est un agent neuroprotecteur, un agent thrombolytique, un antagoniste de la glycoprotéine IIb IIIa, ou un anticorps anti-CD18.
EP07840638.6A 2006-08-29 2007-08-01 Méthode de traitement d'avc à l'aide d'un agent thrombolytique Active EP2056856B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82386806P 2006-08-29 2006-08-29
PCT/US2007/074997 WO2008027687A2 (fr) 2006-08-29 2007-08-01 Méthode de traitement d'avc à l'aide d'un agent thrombolytique

Publications (2)

Publication Number Publication Date
EP2056856A2 EP2056856A2 (fr) 2009-05-13
EP2056856B1 true EP2056856B1 (fr) 2015-01-14

Family

ID=38835003

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07840638.6A Active EP2056856B1 (fr) 2006-08-29 2007-08-01 Méthode de traitement d'avc à l'aide d'un agent thrombolytique

Country Status (22)

Country Link
US (2) US20080107641A1 (fr)
EP (1) EP2056856B1 (fr)
JP (1) JP5785687B2 (fr)
KR (1) KR20090045405A (fr)
CN (1) CN101505785A (fr)
AU (1) AU2007290277B2 (fr)
BR (1) BRPI0716143A2 (fr)
CA (1) CA2661012C (fr)
CO (1) CO6150188A2 (fr)
EA (1) EA015573B1 (fr)
EC (1) ECSP099178A (fr)
HK (1) HK1131054A1 (fr)
IL (2) IL196987A (fr)
MX (1) MX2009001918A (fr)
MY (1) MY163119A (fr)
NO (1) NO342302B1 (fr)
NZ (1) NZ574767A (fr)
SG (3) SG174753A1 (fr)
TW (1) TWI439282B (fr)
UA (1) UA97486C2 (fr)
WO (1) WO2008027687A2 (fr)
ZA (1) ZA200900957B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
EP2540696B1 (fr) 2005-02-24 2020-01-01 Diffusion Pharmaceuticals LLC Transcaroténoïdes, formulation les comprenant et leurs utilisations
AU2007290277B2 (en) 2006-08-29 2013-04-11 Genentech, Inc. Use of tenecteplase for treating acute ischemic stroke
KR101570131B1 (ko) 2007-04-13 2015-11-18 디퓨젼 파마슈티컬즈 엘엘씨 양극성 트랜스 카로티노이드의 말초혈관질환 치료와 예방을 위한 용도
US9034007B2 (en) 2007-09-21 2015-05-19 Insera Therapeutics, Inc. Distal embolic protection devices with a variable thickness microguidewire and methods for their use
US20110257510A1 (en) * 2008-12-24 2011-10-20 Koninklijke Philips Electronics N.V. System, method and apparatus for cardiac intervention with mr stroke detection and treatment
EP2445339B1 (fr) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Composé améliorant la diffusion et son utilisation avec un thrombolytique
US10555915B2 (en) 2009-08-24 2020-02-11 Hough Ear Institute Methods for treating acute acoustic trauma
CN105287473A (zh) 2010-06-02 2016-02-03 扩散药品有限公司 包含双极性反式类胡萝卜素的组合物及其应用
BR112013015914B1 (pt) * 2010-12-23 2021-06-08 Gennova Biopharmaceuticals Ltd. composições farmacêuticas de tenecteplase
WO2014062888A1 (fr) * 2012-10-18 2014-04-24 University Of South Florida Compositions et procédés de traitement d'accident vasculaire cérébral
US8679150B1 (en) 2013-03-15 2014-03-25 Insera Therapeutics, Inc. Shape-set textile structure based mechanical thrombectomy methods
US8715315B1 (en) 2013-03-15 2014-05-06 Insera Therapeutics, Inc. Vascular treatment systems
US8715314B1 (en) 2013-03-15 2014-05-06 Insera Therapeutics, Inc. Vascular treatment measurement methods
CN109730806B (zh) 2013-03-15 2023-01-24 伊瑟拉医疗公司 脉管治疗装置和方法
WO2015023830A1 (fr) 2013-08-14 2015-02-19 Stc.Unm Traitement et prévention d'un accident vasculaire cérébral et d'autres troubles neurologiques
ES2829923T3 (es) * 2014-10-21 2021-06-02 Gennova Biopharmaceuticals Ltd Un proceso novedoso de purificación para el aislamiento y la producción comercial de tnk-tpa recombinante (tenecteplase)
CN108697423A (zh) 2016-02-16 2018-10-23 伊瑟拉医疗公司 抽吸装置和锚定的分流装置
WO2017165667A1 (fr) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Utilisation de caroténoïdes trans bipolaires avec une chimiothérapie et une radiothérapie en vue du traitement d'un cancer
CA3050858A1 (fr) * 2017-01-24 2018-08-02 Ekos Corporation Methode pour le traitement de la thrombo-embolie
WO2018210860A1 (fr) * 2017-05-16 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement d'un accident vasculaire ischémique cérébral aigu
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
WO2021158799A1 (fr) * 2020-02-04 2021-08-12 The Regents Of The University Of Colorado, A Body Corporate Utilisations prophylactiques de l'annexine a2

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU664469B2 (en) 1992-06-03 1995-11-16 Genentech Inc. Tissue plasminogen activator glycosylation variants with improved therapeutic properties
JP2002173447A (ja) * 2000-09-29 2002-06-21 Yamanouchi Pharmaceut Co Ltd 脳塞栓症治療用医薬組成物
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US20030180282A1 (en) * 2002-03-25 2003-09-25 Victor Serebruany Method of treatment of thrombotic events
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
WO2006094120A2 (fr) * 2005-03-02 2006-09-08 The Regents Of The University Of California Traitement d'une embolie cerebro-vasculaire
AU2007290277B2 (en) 2006-08-29 2013-04-11 Genentech, Inc. Use of tenecteplase for treating acute ischemic stroke

Also Published As

Publication number Publication date
SG10201501498VA (en) 2015-04-29
JP2010502629A (ja) 2010-01-28
IL196987A0 (en) 2011-08-01
NO342302B1 (no) 2018-04-30
WO2008027687A3 (fr) 2008-05-22
ZA200900957B (en) 2010-05-26
EA015573B1 (ru) 2011-10-31
MX2009001918A (es) 2009-03-06
UA97486C2 (ru) 2012-02-27
NZ574767A (en) 2012-02-24
ECSP099178A (es) 2009-06-30
IL196987A (en) 2016-10-31
US20120164157A1 (en) 2012-06-28
SG174753A1 (en) 2011-10-28
JP5785687B2 (ja) 2015-09-30
TW200817033A (en) 2008-04-16
TWI439282B (zh) 2014-06-01
AU2007290277A1 (en) 2008-03-06
KR20090045405A (ko) 2009-05-07
US20080107641A1 (en) 2008-05-08
US9023346B2 (en) 2015-05-05
HK1131054A1 (en) 2010-01-15
EA200970237A1 (ru) 2009-08-28
IL248176A0 (en) 2016-11-30
AU2007290277B2 (en) 2013-04-11
NO20091296L (no) 2009-05-28
CA2661012C (fr) 2019-03-19
CA2661012A1 (fr) 2008-03-06
EP2056856A2 (fr) 2009-05-13
CO6150188A2 (es) 2010-04-20
SG10201804944XA (en) 2018-07-30
WO2008027687A2 (fr) 2008-03-06
BRPI0716143A2 (pt) 2013-11-26
CN101505785A (zh) 2009-08-12
MY163119A (en) 2017-08-15

Similar Documents

Publication Publication Date Title
EP2056856B1 (fr) Méthode de traitement d'avc à l'aide d'un agent thrombolytique
DE69503120T3 (de) Zusammensetzungen aus einer thrombolytisch wirkende substanz und antikoagulantien, und ihre verwendungen
US20190216905A1 (en) TPP-1 Formulations and Methods for Treating CLN2 Disease
US20090004177A1 (en) Combination Treatment with t-PA Variant and Low Molecular Weight Heparin
Furlan et al. Thrombolytic therapy in acute ischemic stroke
Broderick Recanalization therapies for acute ischemic stroke
US20220073888A1 (en) Combination treatment
US20130058939A1 (en) Treatment of neurological or neurodegenerative disorders
Brott Reopening occluded cerebral arteries
EP4245312A1 (fr) Régimes d'antagonistes de vegf étendus et à dose élevée pour le traitement de troubles oculaires angiogéniques
JP2022551373A (ja) 三環式誘導体を用いた脳卒中の治療方法
Marè et al. Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke
Spinler et al. Update on strategies to improve thrombolysis for acute myocardial infarction
Weiner Thrombolytic agents in critical care
KR20210014024A (ko) 트리사이클릭 유도체를 이용한 뇌졸중의 치료 방법
KR100831770B1 (ko) ｔ-ＰＡ 변이체와 저분자량 헤파린의 조합 치료
Hoang et al. The efficacy and safety of tissue plasminogen activator in acute ischemic strokes
CN117295497A (zh) 用于治疗脑梗塞的药物组合物
JP2008507561A (ja) 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
WO2007134813A2 (fr) Procédé pour traiter une thromboembolie veineuse
EP2289541A1 (fr) Traitement des troubles neurologiques ou neuro-dégénératifs
Diaz-Ricart Desmoteplase
Zhang et al. Safety of tirofiban for patients with acute ischemic stroke in routine clinical practice
Csiba et al. Fibrin-degrading drugs in acute stroke
Walsh Tissue Plasminogen Activator-Based Thrombolytic Agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090317

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131054

Country of ref document: HK

17Q First examination report despatched

Effective date: 20130827

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140804

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 706646

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007040078

Country of ref document: DE

Effective date: 20150226

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER AND PEDRAZZINI AG, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20150114

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 706646

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150114

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150414

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1131054

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150514

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150415

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007040078

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20151015

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20070801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150114

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230420

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20230902

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240723

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240723

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240723

Year of fee payment: 18